Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products. The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 12 616 M
EBIT 2014 3 376 M
Net income 2014 1 462 M
Debt 2014 13 965 M
Yield 2014 -
Sales 2015 15 545 M
EBIT 2015 5 233 M
Net income 2015 2 895 M
Debt 2015 9 839 M
Yield 2015 -
PER 2014 29,19
PER 2015 17,12
EV / Sales 2014 5,62x
EV / Sales 2015 4,30x
Capitalization 56 951 M
More Financials
Latest news on ACTAVIS INC
1d ago AstraZeneca buys Almirall lung drugs for up to $2.1 billion
3d ago Pfizer's need for deal looms larger with earnings report
07/21 ACTAVIS : Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for..
07/21 ACTAVIS : Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for..
07/14DJU.S. HOT STOCKS : Hot Stocks to Watch
07/11 ACTAVIS : Confirms Generic Diclegis® Patent Challenge
07/08 ACTAVIS : Confirms Generic Ampyra® Patent Challenge
07/02 ACTAVIS : Impax Acquires Two Products from Actavis
07/02 ACTAVIS : Announces Final Stockholder Merger Consideration Election Results in C..
07/01 ACTAVIS : Completes Forest Laboratories Acquisition
07/01 ACTAVIS : Appoints New Members and Announces Changes to Board of Directors Follo..
07/01 ACTAVIS : Stocks Coverage on the Pharma Industry -- Research on Zoetis, Mylan, A..
More news
Comments 
Advertisement
Income Statement Evolution
Actavis Inc : Income Statement Evolution
More Financials
EPS Revisions
Actavis Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF